SGP: Innovative IOL delivers glaucoma therapy during cataract surgery, aiming for 2029 launch
A novel intraocular lens with integrated drug delivery targets a $13 billion market by simplifying glaucoma and cataract treatment in a single procedure, showing strong clinical efficacy and safety. Phase III trials are underway, with a potential launch in 2029.Based on SpyGlass Pharma, Inc. [SGP…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.